Analysis of Bcl-2, PTEN, p53, and Ki-67 expressions in endometrial cancer arising from endometrial polyp

Objective: To compare the expression of the proliferation marker Ki-67, the antiapoptotic protein Bcl-2, and the tumor suppressor genes p53 and PTEN between endometrial cancer arising from endometrial polyp and benign endometrial polyps. Materials and Methods: The study was performed retrospectively in 40 patients treated at the present institution between 2006-2011. A total of 20 cases that had endometrial cancer arising from endometrial polyp that met study criteria were included consecutively in the study. For each malign case, one case that had a benign endometrial polyp diagnosed at hysterectomy specimen was included in the study. Results: The Ki-67 score was significantly higher in endometrial cancer arising from endometrial polyp group in comparison to the benign polyps (p < 0.05). However, the Bcl-2 expression was significantly lower in the endometrial cancer arising from endometrial polyp when compared to the benign polyps (p < 0.05). PTEN and p53 expressions were not different between groups (p > 0.05). In patients with endometrial cancer, Ki-67, Bcl-2, PTEN, and p53 expressions were not different among histological type, stage, grade, myometrial invasion, polyp size, and lymphovascular space invasion, with an exception of p53. p53 expression was significantly increased in higher grade tumors (p < 0.05). Conclusion: The results of the present study indicate that there is an inhibition of apoptosis and a decrease in proliferation in benign endometrial polyps. Possibly, at carcinogenesis step of endometrial cancer developed from benign polyp, other additional mutations cause a reverse effect and they increase proliferation and prevent the apoptosis inhibition.

Endometrial cancer; Polyp; Malignancy; p53; Bcl-2; Ki-67; PTEN

[1] Litta P., Di Giuseppe J., Moriconi L., Delli Carpini G., Piermartiri M.G., Ciavattini A.: “Predictors of malignancy in endometrial polyps: a multi-institutional cohort study”. Eur. J. Gynaecol. Oncol., 2014, 35, 382.

[2] Urabe R., Hachisuga T., Kurita T., Kagami S., Kawagoe T., Matsuura Y., et al.: “Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade”. J. Obstet. Gynaecol. Res., 2014, 40, 812.

[3] Dobrzycka B., Terlikowski S.J., Garbowicz M., Niklinski J., Chyczewski L., Kulikowski M.: “The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer”. Folia Histochem. Cytobiol., 2011, 49, 631.

[4] Djordjevic B., Hennessy B.T., Li J., Barkoh B.A., Luthra R., Mills G.B., et al.: “Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing”.. Mod. Pathol., 2012, 25, 699.

[5] Garg K., Broaddus R.R., Soslow R.A., Urbauer D.L., Levine D.A., Djordjevic B.: “Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible”. Int. J. Gynecol. Pathol., 2012, 31, 48.

[6] Stoian S.C., Simionescu C., Margaritescu C., Stepan A., Nurciu M.: “Endometrial carcinomas: correlation between ER, PR, Ki67 status and histopathological prognostic parameters”. Rom. J. Morphol. Embryol., 2011, 52, 631.

[7] Risberg B., Karlsson K., Abeler V., Lagrelius A., Davidson B., Karlsson M.G.: “Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications”. Int. J. Gynecol. Pathol., 2002, 21, 155.

[8] Quddus M.R., Ologun B.A., Sung C.J., Steinhoff M.M., Lawrence W.D.: “Utility of PTEN expression of endometrial “surface epithelial changes” and underlying atypical endometrial hyperplasia”. Int. J. Gynecol. Pathol., 2009, 28, 471.

[9] Taylor L.J., Jackson T.L., Reid J.G., Duffy S.R.: “The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps”. BJOG, 2003, 110, 794.

[10] Morsi H.M., Leers M.P., Jager W., Bjorklund V., Radespiel-Troger M., el Kabarity H., et al.: “The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium”. Int. J. Gynecol. Pathol., 2000, 19, 118.

[11] Apostolou G., Apostolou N., Biteli M., Kavantzas N., Patsouris E., Athanassiadou P.: “Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology”. Diagn. Cytopathol., 2014, 42, 134.

[12] Liu F.S.: “Molecular carcinogenesis of endometrial cancer”. Taiwan J. Obstet. Gynecol., 2007, 46, 26.

[13] McCluggage W.G., Sumathi V.P., McManus D.T.: “Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy”. Hum. Pathol., 2003, 34, 939.

[14] Trahan S., Tetu B., Raymond P.E.: “Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases”. Hum. Pathol., 2005, 36, 1316.

[15] Giordano G., Gnetti L., Merisio C., Melpignano M.: “Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps”. Maturitas, 2007, 56, 190.

[16] Zhu C., Luo J., Shi H., Xie X., Ding Z.: “Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer”. Eur. J. Gynaecol. Oncol., 2009, 30, 514.

[17] Mitselou A., Ioachim E., Kitsou E., Vougiouklakis T., Zagorianakou N., Makrydimas G., et al.: “Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene cerbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium”. In Vivo, 2003, 17, 469.

[18] Daniilidou K., Frangou-Plemenou M., Grammatikakis J., Grigoriou O., Vitoratos N., Kondi-Pafiti A.: “Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study”. J. BUON., 2013, 18, 195.

[19] Inaba F., Kawamata H., Teramoto T., Fukasawa I., Inaba N., Fujimori T.: “PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma”. Oncol. Rep., 2005, 13, 17.

[20] Farrell R., Scurry J., Otton G., Hacker N.F.: “Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium”. Gynecol. Oncol., 2005, 98, 254.

[21] Ilker S., Elmas K., Emre O., Mengu T., Erkaya S., Tayfun G.: “Lympho-vascular space invasion indicates advanced disease for uterine papillary serous tumors arising from polyps”. Asian Pac. J. Cancer, Prev., 2015, 16, 4257.

[22] Mossa B., Torcia F., Avenoso F., Tucci S., Marziani R.: “Occurrence of malignancy in endometrial polyps during postmenopause”. Eur. J. Gynaecol. Oncol., 2010, 31, 165.

[23] Idrees R., Din N.U., Fatima S., Kayani N.: “Serous carcinoma arising in endometrial polyps: clinicopathologic study of 4 cases”. Ann. Diagn. Pathol., 2013, 17, 256.

[24] Ben-Arie A., Goldchmit C., Laviv Y., Levy R., Caspi B., Huszar M., et al.: “The malignant potential of endometrial polyps”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 115, 206.

[25] Wethington S.L., Herzog T.J., Burke W.M., Sun X., Lerner J.P., Lewin S.N., et al.: “Risk and predictors of malignancy in women with endometrial polyps”. Ann. Surg. Oncol., 2011, 18, 3819.

[26] Lee S.C., Kaunitz A.M., Sanchez-Ramos L., Rhatigan R.M.: “The oncogenic potential of endometrial polyps: a systematic review and meta-analysis”. Obstet. Gynecol., 2010, 116, 1197.

[27] Hileeto D., Fadare O., Martel M., Zheng W.: “Age dependent association of endometrial polyps with increased risk of cancer involvement”. world J. Surg. Oncol., 2005, 3, 8.

[28] Pergialiotis V,. Prodromidou A., Siotos C., Frountzas M., Perrea D., Vlachos G.D.: “Systemic hypertension and diabetes mellitus as predictors of malignancy among women with endometrial polyps: a meta-analysis of observational studies”. Menopause, 2016, 23, 691.

[29] Arem H., Irwin M.L.: “Obesity and endometrial cancer survival: a systematic review”. Int. J. Obes. (Lond.), 2013, 37, 634.

[30] Nappi L., Indraccolo U., Di Spiezio Sardo A., Gentile G., Palombino K., Castaldi M.A., et al.: “Are diabetes, hypertension, and obesity independent risk factors for endometrial polyps?” J. Minim. Invasive Gynecol., 2009, 16, 157.

[31] Wheeler D.T., Bell K.A., Kurman R.J., Sherman M.E.: “Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation”. Am. J. Surg. Pathol., 2000, 24, 797.

[32] Baergen R.N., Warren C.D., Isacson C., Ellenson L.H.: “Early uterine serous carcinoma: clonal origin of extrauterine disease”. Int. J. Gynecol. Pathol., 2001, 20, 214.

[33] Zheng W., Liang S.X., Yu H., Rutherford T., Chambers S.K., Schwartz P.E.: “Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features”. Int. J. Surg. Pathol., 2004, 12, 207.

[34] Hui P., Kelly M., O’Malley D.M., Tavassoli F., Schwartz P.E.: “Minimal uterine serous carcinoma: a clinicopathological study of 40 cases”. Mod. Pathol., 2005, 18, 75.

[35] Jia L., Liu Y., Yi X., Miron A., Crum C.P., Kong B., et al.: “Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma”. Clin. Cancer Res., 2008, 14, 2263.

[36] Yan Z., Hui P.: “Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases”. Appl. Immunohistochem. Mol. Morphol., 2010, 18, 75.

[37] Antunes A., Jr., Andrade L.A., Pinto G.A., Leao R., Pinto-Neto A.M., Costa-Paiva L.: “Is the immunohistochemical expression of proliferation (Ki-67) and apoptosis (Bcl-2) markers and cyclooxigenase2 (COX-2) related to carcinogenesis in postmenopausal endometrial polyps?” Anal. Quant. Cytopathol. Histpathol., 2012, 34, 264.

[38] Pathiraja P., Dhar S., Haldar K.: “Serous endometrial intraepithelial carcinoma: a case series and literature review”. Cancer Manag. Res., 2013, 5, 117.

[39] Yasuda M., Katoh T., Hori S., Suzuki K., Ohno K., Maruyama M., et al.: “Endometrial intraepithelial carcinoma in association with polyp: review of eight cases”. Diagn. Pathol., 2013, 8, 25.

[40] Ono K., Hayashi H., Tateno M., Tanaka R., Suzuki R., Maruyama Y., et al.: “Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients”. Int. J. Clin. Exp. Pathol., 2014, 7, 7979.